Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness in Patients With Hemorrhagic Stroke: A Pilot Study

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 29 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 May 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
25 May 2023 Planned primary completion date changed from 31 Dec 2024 to 31 Jul 2025.
23 May 2023 This study protocol has been amended as earlier focus of the study was on Disorder of Consciousness due to Traumatic Brain Injuries and now it turned to Disorder of Consciousness due to Hemorrhagic Stroke, Number of treatment arms changed to 2, Amantadine sulfate has been removed from the study, Patient age criteria changed to 18-120 from 18-64.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com